TW209863B - - Google Patents
Download PDFInfo
- Publication number
- TW209863B TW209863B TW080109502A TW80109502A TW209863B TW 209863 B TW209863 B TW 209863B TW 080109502 A TW080109502 A TW 080109502A TW 80109502 A TW80109502 A TW 80109502A TW 209863 B TW209863 B TW 209863B
- Authority
- TW
- Taiwan
- Prior art keywords
- formula
- group
- methyl
- acid
- compound
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 claims abstract description 22
- 238000011282 treatment Methods 0.000 claims abstract description 7
- 230000000694 effects Effects 0.000 claims abstract description 6
- 206010020772 Hypertension Diseases 0.000 claims abstract description 3
- 150000001875 compounds Chemical class 0.000 claims description 57
- -1 6-keto 3-pyridyl Chemical group 0.000 claims description 35
- 239000007921 spray Substances 0.000 claims description 27
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 19
- 238000011049 filling Methods 0.000 claims description 17
- 239000002253 acid Substances 0.000 claims description 15
- 150000002576 ketones Chemical class 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- VKEQBMCRQDSRET-UHFFFAOYSA-N Methylone Chemical compound CNC(C)C(=O)C1=CC=C2OCOC2=C1 VKEQBMCRQDSRET-UHFFFAOYSA-N 0.000 claims description 4
- 150000001412 amines Chemical class 0.000 claims description 4
- 238000000855 fermentation Methods 0.000 claims description 4
- 230000004151 fermentation Effects 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 241000699670 Mus sp. Species 0.000 claims description 3
- 230000008859 change Effects 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 238000010306 acid treatment Methods 0.000 claims description 2
- 230000002040 relaxant effect Effects 0.000 claims description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 claims 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 230000036772 blood pressure Effects 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 230000008602 contraction Effects 0.000 claims 1
- 210000004351 coronary vessel Anatomy 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 230000002102 hyperpolarization Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 210000001147 pulmonary artery Anatomy 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 abstract description 3
- 210000000748 cardiovascular system Anatomy 0.000 abstract description 3
- 206010002383 Angina Pectoris Diseases 0.000 abstract description 2
- 206010019280 Heart failures Diseases 0.000 abstract description 2
- 231100000360 alopecia Toxicity 0.000 abstract description 2
- 206010021639 Incontinence Diseases 0.000 abstract 1
- VZWXIQHBIQLMPN-UHFFFAOYSA-N chromane Chemical class C1=CC=C2CCCOC2=C1 VZWXIQHBIQLMPN-UHFFFAOYSA-N 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 239000007789 gas Substances 0.000 description 22
- 235000019441 ethanol Nutrition 0.000 description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical group O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 15
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 229910052740 iodine Inorganic materials 0.000 description 15
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 14
- 239000002585 base Substances 0.000 description 13
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 125000003277 amino group Chemical group 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 10
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 8
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 7
- 125000004429 atom Chemical group 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical group CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 6
- 229910052794 bromium Inorganic materials 0.000 description 6
- 230000000875 corresponding effect Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 6
- KLSJWNVTNUYHDU-UHFFFAOYSA-N Amitrole Chemical compound NC1=NC=NN1 KLSJWNVTNUYHDU-UHFFFAOYSA-N 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 239000000460 chlorine Substances 0.000 description 5
- 229910052801 chlorine Inorganic materials 0.000 description 5
- 229910052731 fluorine Inorganic materials 0.000 description 5
- 239000012442 inert solvent Substances 0.000 description 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- MMWRGWQTAMNAFC-UHFFFAOYSA-N 1,2-dihydropyridine Chemical compound C1NC=CC=C1 MMWRGWQTAMNAFC-UHFFFAOYSA-N 0.000 description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 4
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical group CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 125000002947 alkylene group Chemical group 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 235000019253 formic acid Nutrition 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 4
- 125000004076 pyridyl group Chemical group 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- XTKDAFGWCDAMPY-UHFFFAOYSA-N azaperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCN(C=2N=CC=CC=2)CC1 XTKDAFGWCDAMPY-UHFFFAOYSA-N 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 125000004093 cyano group Chemical group *C#N 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229940033134 talc Drugs 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 239000011975 tartaric acid Substances 0.000 description 3
- 235000002906 tartaric acid Nutrition 0.000 description 3
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 2
- RIZGKEIRSQLIBK-NSCUHMNNSA-N 1-propene-1-thiol Chemical group C\C=C\S RIZGKEIRSQLIBK-NSCUHMNNSA-N 0.000 description 2
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 2
- 239000001431 2-methylbenzaldehyde Substances 0.000 description 2
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000040350 B family Human genes 0.000 description 2
- 108091072128 B family Proteins 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N Camphoric acid Natural products CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 239000005562 Glyphosate Substances 0.000 description 2
- AMIMRNSIRUDHCM-UHFFFAOYSA-N Isopropylaldehyde Chemical group CC(C)C=O AMIMRNSIRUDHCM-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- 240000002853 Nelumbo nucifera Species 0.000 description 2
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 2
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 206010041349 Somnolence Diseases 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical compound CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000002079 cooperative effect Effects 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000002309 gasification Methods 0.000 description 2
- 229940097068 glyphosate Drugs 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 238000007037 hydroformylation reaction Methods 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 2
- TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical compound OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 2
- CYEBJEDOHLIWNP-UHFFFAOYSA-N methanethioamide Chemical compound NC=S CYEBJEDOHLIWNP-UHFFFAOYSA-N 0.000 description 2
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- 238000006396 nitration reaction Methods 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 235000011007 phosphoric acid Nutrition 0.000 description 2
- WLJVNTCWHIRURA-UHFFFAOYSA-N pimelic acid Chemical compound OC(=O)CCCCCC(O)=O WLJVNTCWHIRURA-UHFFFAOYSA-N 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 229960004063 propylene glycol Drugs 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N protonated dimethyl amine Natural products CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- XOVSRHHCHKUFKM-UHFFFAOYSA-N s-methylthiohydroxylamine Chemical compound CSN XOVSRHHCHKUFKM-UHFFFAOYSA-N 0.000 description 2
- SMQUZDBALVYZAC-UHFFFAOYSA-N salicylaldehyde Chemical compound OC1=CC=CC=C1C=O SMQUZDBALVYZAC-UHFFFAOYSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 150000003335 secondary amines Chemical group 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- SEPPVOUBHWNCAW-FNORWQNLSA-N (E)-4-oxonon-2-enal Chemical compound CCCCCC(=O)\C=C\C=O SEPPVOUBHWNCAW-FNORWQNLSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- QMMOXUPEWRXHJS-HYXAFXHYSA-N (z)-pent-2-ene Chemical compound CC\C=C/C QMMOXUPEWRXHJS-HYXAFXHYSA-N 0.000 description 1
- UOCLXMDMGBRAIB-UHFFFAOYSA-N 1,1,1-trichloroethane Chemical compound CC(Cl)(Cl)Cl UOCLXMDMGBRAIB-UHFFFAOYSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- KPZGRMZPZLOPBS-UHFFFAOYSA-N 1,3-dichloro-2,2-bis(chloromethyl)propane Chemical compound ClCC(CCl)(CCl)CCl KPZGRMZPZLOPBS-UHFFFAOYSA-N 0.000 description 1
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 1
- JADBQNNRRQRIFM-UHFFFAOYSA-N 1-aminopyridin-2-one Chemical compound NN1C=CC=CC1=O JADBQNNRRQRIFM-UHFFFAOYSA-N 0.000 description 1
- HLVFKOKELQSXIQ-UHFFFAOYSA-N 1-bromo-2-methylpropane Chemical compound CC(C)CBr HLVFKOKELQSXIQ-UHFFFAOYSA-N 0.000 description 1
- MTSQHZHIEDRSOM-UHFFFAOYSA-N 1-ethylpyridin-2-one Chemical compound CCN1C=CC=CC1=O MTSQHZHIEDRSOM-UHFFFAOYSA-N 0.000 description 1
- DVVGIUUJYPYENY-UHFFFAOYSA-N 1-methylpyridin-2-one Chemical compound CN1C=CC=CC1=O DVVGIUUJYPYENY-UHFFFAOYSA-N 0.000 description 1
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 description 1
- OXQGTIUCKGYOAA-UHFFFAOYSA-N 2-Ethylbutanoic acid Chemical compound CCC(CC)C(O)=O OXQGTIUCKGYOAA-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 description 1
- ZWVHTXAYIKBMEE-UHFFFAOYSA-N 2-hydroxyacetophenone Chemical compound OCC(=O)C1=CC=CC=C1 ZWVHTXAYIKBMEE-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- YNJSNEKCXVFDKW-UHFFFAOYSA-N 3-(5-amino-1h-indol-3-yl)-2-azaniumylpropanoate Chemical compound C1=C(N)C=C2C(CC(N)C(O)=O)=CNC2=C1 YNJSNEKCXVFDKW-UHFFFAOYSA-N 0.000 description 1
- XUHLIQGRKRUKPH-ITZCMCNPSA-N 3-(Allylsulphinyl)-L-alanine Chemical compound OC(=O)[C@@H](N)CS(=O)CC=C XUHLIQGRKRUKPH-ITZCMCNPSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- RXXCIBALSKQCAE-UHFFFAOYSA-N 3-methylbutoxymethylbenzene Chemical compound CC(C)CCOCC1=CC=CC=C1 RXXCIBALSKQCAE-UHFFFAOYSA-N 0.000 description 1
- LLBZPESJRQGYMB-UHFFFAOYSA-N 4-one Natural products O1C(C(=O)CC)CC(C)C11C2(C)CCC(C3(C)C(C(C)(CO)C(OC4C(C(O)C(O)C(COC5C(C(O)C(O)CO5)OC5C(C(OC6C(C(O)C(O)C(CO)O6)O)C(O)C(CO)O5)OC5C(C(O)C(O)C(C)O5)O)O4)O)CC3)CC3)=C3C2(C)CC1 LLBZPESJRQGYMB-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- OQHLYZTVUZZSRR-UHFFFAOYSA-N 5-amino-1-methylpyridin-2-one Chemical compound CN1C=C(N)C=CC1=O OQHLYZTVUZZSRR-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 108091071247 Beta family Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- GZBPUSHAGXSMDT-UHFFFAOYSA-N C(C)NCC.C=O Chemical group C(C)NCC.C=O GZBPUSHAGXSMDT-UHFFFAOYSA-N 0.000 description 1
- SGZSPSSQMKENGW-UHFFFAOYSA-N C=O.CCN Chemical compound C=O.CCN SGZSPSSQMKENGW-UHFFFAOYSA-N 0.000 description 1
- VCRTUEWZYXRBFN-UHFFFAOYSA-N CCS(=O)=O Chemical group CCS(=O)=O VCRTUEWZYXRBFN-UHFFFAOYSA-N 0.000 description 1
- 101100219382 Caenorhabditis elegans cah-2 gene Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 241001669679 Eleotris Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 229910021055 KNH2 Inorganic materials 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 229910020667 PBr3 Inorganic materials 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical group CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000012345 acetylating agent Substances 0.000 description 1
- 230000000397 acetylating effect Effects 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000002535 acidifier Substances 0.000 description 1
- 229940095602 acidifiers Drugs 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000003679 aging effect Effects 0.000 description 1
- 150000001335 aliphatic alkanes Chemical group 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- HUMNYLRZRPPJDN-KWCOIAHCSA-N benzaldehyde Chemical group O=[11CH]C1=CC=CC=C1 HUMNYLRZRPPJDN-KWCOIAHCSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- 229940073608 benzyl chloride Drugs 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000007322 compensatory function Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000012024 dehydrating agents Substances 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 210000004268 dentin Anatomy 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 1
- 125000006263 dimethyl aminosulfonyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- ZCRZCMUDOWDGOB-UHFFFAOYSA-N ethanesulfonimidic acid Chemical group CCS(N)(=O)=O ZCRZCMUDOWDGOB-UHFFFAOYSA-N 0.000 description 1
- QJFUMFCCMJJLIE-UHFFFAOYSA-N ethanethial Chemical group CC=S QJFUMFCCMJJLIE-UHFFFAOYSA-N 0.000 description 1
- LOYAISKUPWWDKD-UHFFFAOYSA-N ethoxymethanesulfonamide Chemical compound CCOCS(N)(=O)=O LOYAISKUPWWDKD-UHFFFAOYSA-N 0.000 description 1
- MJEMIOXXNCZZFK-UHFFFAOYSA-N ethylone Chemical compound CCNC(C)C(=O)C1=CC=C2OCOC2=C1 MJEMIOXXNCZZFK-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- XDDAORKBJWWYJS-UHFFFAOYSA-N glyphosate Chemical compound OC(=O)CNCP(O)(O)=O XDDAORKBJWWYJS-UHFFFAOYSA-N 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- JARKCYVAAOWBJS-UHFFFAOYSA-N hexanal Chemical group CCCCCC=O JARKCYVAAOWBJS-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- YPGCWEMNNLXISK-UHFFFAOYSA-N hydratropic acid Chemical compound OC(=O)C(C)C1=CC=CC=C1 YPGCWEMNNLXISK-UHFFFAOYSA-N 0.000 description 1
- 150000002483 hydrogen compounds Chemical class 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- OVWYEQOVUDKZNU-UHFFFAOYSA-N m-tolualdehyde Chemical compound CC1=CC=CC(C=O)=C1 OVWYEQOVUDKZNU-UHFFFAOYSA-N 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- PZOSKZSXQBFGDL-UHFFFAOYSA-N methanethioamide N-methylmethanamine Chemical group CNC.C(=S)N PZOSKZSXQBFGDL-UHFFFAOYSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- NPYKGRVVEMGBQK-UHFFFAOYSA-N methyl(oxo)sulfanium Chemical group C[S+]=O NPYKGRVVEMGBQK-UHFFFAOYSA-N 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- SNMVRZFUUCLYTO-UHFFFAOYSA-N n-propyl chloride Chemical compound CCCCl SNMVRZFUUCLYTO-UHFFFAOYSA-N 0.000 description 1
- GKAOGPIIYCISHV-UHFFFAOYSA-N neon atom Chemical group [Ne] GKAOGPIIYCISHV-UHFFFAOYSA-N 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 150000002825 nitriles Chemical group 0.000 description 1
- 150000002828 nitro derivatives Chemical class 0.000 description 1
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 1
- BTFQKIATRPGRBS-UHFFFAOYSA-N o-tolualdehyde Chemical compound CC1=CC=CC=C1C=O BTFQKIATRPGRBS-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 238000006053 organic reaction Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 150000002900 organolithium compounds Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- FXLOVSHXALFLKQ-UHFFFAOYSA-N p-tolualdehyde Chemical group CC1=CC=C(C=O)C=C1 FXLOVSHXALFLKQ-UHFFFAOYSA-N 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- HGBOYTHUEUWSSQ-UHFFFAOYSA-N pentanal Chemical group CCCCC=O HGBOYTHUEUWSSQ-UHFFFAOYSA-N 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- IPNPIHIZVLFAFP-UHFFFAOYSA-N phosphorus tribromide Chemical compound BrP(Br)Br IPNPIHIZVLFAFP-UHFFFAOYSA-N 0.000 description 1
- 235000021110 pickles Nutrition 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical class OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- CUQOHAYJWVTKDE-UHFFFAOYSA-N potassium;butan-1-olate Chemical compound [K+].CCCC[O-] CUQOHAYJWVTKDE-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003141 primary amines Chemical group 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 1
- 229940080818 propionamide Drugs 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 229910052705 radium Inorganic materials 0.000 description 1
- SYUHGPGVQRZVTB-UHFFFAOYSA-N radon atom Chemical group [Rn] SYUHGPGVQRZVTB-UHFFFAOYSA-N 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 229910052702 rhenium Inorganic materials 0.000 description 1
- WDSFCZDGCAXRDY-UHFFFAOYSA-N s-ethylthiohydroxylamine Chemical compound CCSN WDSFCZDGCAXRDY-UHFFFAOYSA-N 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 150000003385 sodium Chemical class 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 125000001010 sulfinic acid amide group Chemical group 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 125000000565 sulfonamide group Chemical group 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 150000003459 sulfonic acid esters Chemical class 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 150000003512 tertiary amines Chemical group 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 150000003571 thiolactams Chemical class 0.000 description 1
- 150000003573 thiols Chemical group 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000017105 transposition Effects 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- PSZXPGFNGPBEFR-UHFFFAOYSA-N trisodium butan-1-olate Chemical compound [Na+].[Na+].[Na+].CCCC[O-].CCCC[O-].CCCC[O-] PSZXPGFNGPBEFR-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
A6 B6 五、發明説明(1 ) 本發明傜有關於如式I所示之新穎的喷衍生物
經濟部中央標準而员工消费合作社印製 其中 R 2 為 A, R* , R8與R3各自為Η或A, R2與尺2 合併亦為具3 — 6値硪原子之伸烷基, R 3 為 Η,ΟΗ,ΟΑ 或 0Ri0, R 4 為 Η , R3與R4 合併亦為一値鍵, R 5 為吡啶基,嗒阱基,嘧啶基,吡阱基,酮二 氫吡啶基,酮二氫嗒阱基,酮二氫嘧啶基, 酮二氫吡阱基,且上述基团係未經取代或是 經 A,F,Cl,Br,I,OH,OA, 0Ri0, SH, N〇2 , NH2 , Ri0NH ,HOOC及/或AOOC單取代 與R7 各自為H,A, HO,AO, CHO, ACO, ACS, HOOC, AOOC, AO-CS, ACOO, A-CS-O, HO- CnHin, HS-CnH2n, NO* , (請先閲讀背面之注意事項再填窝本頁) 本紙張尺度逍用中B圉家猱準(CNS)甲4規格(210父297公龙) -3 - 09863 經濟部中央楳準而貝工消费合作社印製 五、發明説明(2 ) NH2,NHA,NA2.CN,F,C1 ,Βγ, I , C F 3 , A S Ο . A S Ο 3 , AO-SO, AO-SOa , R10NH, AO — CO-NH, H2NSO, HANSO, AaNSO, H2NSO2, hans〇2, A^NSO*, H^NCO, HANCO, A^NCO, H»NCS, HANCS, A2NCS, ASONH, ASO2NH, AOSONH, AOSOiNH, ACO-CnH2n, 硝基一 CnHh,氰基一 CnHh, A - C ( = NOH)或 A_C ( = N N H 2), A 為具1一6個碩原子之烷基, RiQ 為具1 一 8個硪原子之烷醯基或具7 — 11 値硝原子之芳醯基,及 η 為 1,2, 3, 4, 5或6 及其鹽類。 本發明像以找尋有用之新穎化合物為目的,特別是那 些可用於製備藥物的化合物。 經發現式I化合物及其生理學上可接受鹽類具備有用 之藥學性質並有良好之耐受性。因此其對心血管糸統有作 用,通常在低劑置時即可觀察到其對冠狀糸統有選擇性之 效用而高劑量時有降低血壓作用。在冠狀糸統中,如降低 (請先閲讀背面之注意事項再填窝本頁) 本紙張尺度逍用中Β困家樣準(CNS)甲4規格(210><297公釐) -4 - 209863 經濟部屮央標準Α员工消f合作社印製 五、發明説明(3 ) 阻抗並增加流置,但對心跳速率無甚大影W。再者這些化 合物對各種平滑肌器官(胃腸道,呼吸条統及子宮)有鬆 弛作用。其作用傺藉由此藝中所知之方法測定,例如 EP-A -76,075, EP-A-168,619, EP-A-173.848 或 A U - A - 4 5,5 4 7 / 8 5 ( D e r w e n t F a r m d o c N 〇 . 8 6 0 817 6 9)及 K.S. Meesmann 等人, Arzneimi ttelforschung 25. (11). 1975.1770-1776。合適之實驗用動物為,例如小鼠,大鼠 ,天竺鼠,狗,貓,猴或豬。 因此這些化合物可作為人類及截類用藥中之活性藥物 。此外其亦可用作為製備其他活性藥物之中間物。 在所述各式中,A較好為具1至6値硪原子之未分枝 烷基/較好為1至4掴磺,特別是1, 2或3®硪,詳細 說來,即較好為甲基,此外亦較好為乙基,丙基,異丙基 ,丁基,異丁基,還有第二丁基,第三丁基,戊基,異戊 基(即3 —甲基丁基),己基或異己基(即4 一甲基戊基 )〇 若R1與R2合併為伸烷基,此伸烷基較好為未分枝 的,詳細説來較好為一 (CH2) m —,其中m為3, 4, 5或6 〇 較好為具1至6値,特別是1, 2, 3或4値硪 原子之烷酵基,詳細說來較好為甲醛基或乙醛基,尚有丙 醯基,丁醯基,異丁醛基,戊醛基或己醛基,此外還有苄 醛基,鄰一,間一或對一甲苯甲醛基,1 一或2 —某甲醯 基。 尺度遑用中β Η家樣準(CNS)甲4規格(210X297公龙) " 一 5 - (請先Μ讀背面之注意事項再填窝本頁) 裝. 訂· 線. 經濟部中央標準:?貝工消费合作杜印製 2〇9B^3 a6 ____B6 _ 五、發明説明(4 ) 與只2較好各為烷基,特別是各為甲基或乙基, 較好各為甲基。 若R4為H, R3較好為〇H,此外為0 — COCH;» 。同理R3與R4合併可為一値鍵。 Rs較好為未經取代之2 -酮一 1, 2 —二氫_1 一 或一 3 -耻症基,4 —酮一 1, 4 一二氫一 3 —社睡基或 為經取代之1, 2—二氫一2-酮一4一吡啶基,特別是 1 一甲基一 1,2 —二氳一 2 —酮一 4 一 Pit症基,尚有未 經取代或是經取代之6—酮一1, 6_二氫一3_嗒阱基 ,特別是其1一位置上經甲基,乙基,異丙基或笮基取代 之6 —酮一 1, 6 —二氫一 3 —嗒阱基。R3另可為2 — ,3-或4一吡啶基,3-或4一嗒阱基· 2—,4一或 5-嘧啶基,2-吡阱基,酮一1, 2-,酮一3,4— 或酮一4, 5—二氫一嘧啶基或酮一1, 2—二氫一吡阱 基,上述各基可為未經取代或單取代或雙取代,較好之取 代基為,如1至6個硪原子之烷基,特別是甲基,乙基或 異丙基,氰,溴,氱,碘,羥基,烷氣基,持別是甲氧基 或乙氧基,胺基,镟基或硝基。 若R5為含有與環中氮原子相鄰之酮基則可互換為内 醯胺。同理,R3若為含有與環中氮原子相鄰之魏基的雜 芳基則可互變為硫代内醛胺,以此類推。 R 5與R 7較好為: A: 甲基,此外還有乙基; A 0 : 甲氣基,此外還有乙氣基; (請先閲讀背面之注意事項再蜞窝本頁) 裝· -訂- 線· 本紙張尺度逍用中Η國家楳準(CNS)甲4規格(210X297公釐) -6 - ΡΊ
經濟部中央標準/t.J员工消费合作社印M 五、發明説明(5 A C 0 : ACS: A Ο 0 C : A Ο - C S : A C 0 0 : A C S O : Η O - C nH in : H S - C nH : N H A : N A a : A S O : A S 0 2 : A ◦ — S 0 A 0 - S 0 R i0N Η : AO — CO — ΝΗ H A N S 0 : 乙醛基,此外還有丙醛基; 硫乙醛基,此外還有硫丙醛基; 甲氣澴基,此外邇有乙氣羰基; 甲氣硫代羰基,此外邇有乙氣硫代 玻基; 乙醛氣基,此外邇有丙酵氣基; 硫代乙醯氣基,此外還有硫代丙醛 氣基; 羥甲基或1 一或2 —羥乙基: 镟甲基或1一或2—魏乙基; 甲胺基,此外還有乙胺基; 二甲胺基,此外通有二乙胺基; 甲亞磺醛基,此外通有乙亞磺醛基 甲磺醯基,此外蓮有乙磺醛基; 甲氣亞磺醯基,此外還有乙氣亞磺 醛基; 甲氣磺醯基,此外還有乙氣磺醯基 乙醛胺基,此外蓮有甲醛胺基,丙 醯胺基,笮醯胺基; 甲氣羰胺基,此外還有乙氣羰胺基 甲胺亞磺醯基,此外邇有乙胺亞磺 (請先閲讀背面之注意事項再填窝本頁) 本紙張尺度逍用中β β家《準(CNS)甲4規格(210X297公釐) _ 7 — 09863 五、發明説明(6 A 2N S 0 : H A N S Ο A 2N S O a : H A N C O : A 2N O C :
H A N C S A C S : A S Ο N H : 經濟部屮央標準局KX工消费合作社印製
A O S Ο N H A O S Ο 2N H : 酵基; 二甲胺亞磺醯基,此外還有二乙胺 亞磺醯基; 甲胺基磺醛基,此外邇有乙胺基横 醛基; 二甲胺基磺醯基,此外還有二乙胺 基磺醯基; N—甲基胺甲醯基,此外還有N— 乙基胺甲醛基; N,N—二甲基胺甲醯基,此外還 有N,N—二乙基胺甲醛基; N —甲基胺(硫甲醯)基,此外還 有N —乙基胺(硫甲醛)基; N,N —二甲基胺(硫甲醯)基, 此外還有N, N —二乙基胺(硫甲 醯)基; 甲基亞磺醯胺基,此外還有乙基亞 磺醯胺基; 甲基磺醯胺基,此外還有乙基磺醯 胺基; 甲氣基亞磺醯胺基,此外還有乙氣 基亞磺醛胺基; 甲氣基磺醯胺基,此外還有乙氣基 磺醯胺基; (請先閲讀背面之注意事項再填寫本頁) 裝· 訂- 線. 本紙張尺度边用中國困家標準(CNS>|甲4規格(210x297公釐) -8 - 09863 η 經濟部中央標準局员工消费合作社印Μ 五、發明説明(7 ) AC0_CnH2n: 2 — 酮丙基,2 —嗣丁基,3 — 振 丁基,3 —酮戊基; 硝基一 C«Hh: 硝甲基,1 一或2 —硝乙基; 氰基一 CnH2n: 氰甲基· 1 一或2 —氰乙基; A - C ( = Ν Ο Η ) ·· 1 一羥亞胺乙基,此外蓮有1 一羥 亞胺丙基; Α — C ( = ΝΝΗ2): 1 —亞肼乙基,此外遢有1 一亞阱 丙基。 變數★ η 〃可為1至6之值,較好為1至2。 Rtf與只7較好在喷条统之6_位置及7 —位置。然 而其亦可位於5 —及6 — · 5 —及7 —,5 —及8_, 6 一及8—與7—及8—位置。 與R7之一較好為H,而另一不為H。而此另一 基圃較好位於6—位置,亦為5-, 7—或8—位置,且 較好為CN或N〇2,此外尚有CHO, ACO (特別是 乙醛基),AOOC (特別是甲氣羰基或乙氣羰基), ACOO (特別是乙睡氣基),還有F, Cl, Br,I ,CF3 , H2NC0, H2NCS 或 ΝΗ2 〇 Re較好為Η,更有甲基或乙基。 根據上述,本發明特別有關於那些式I化合物其取代 基至少有一値具有上述較佳定義。而此化合物之一些較佳 集團可以如下所示之式I a至I j表之,這些化式相對於 式I且其中未詳細定義之基圃具有與式I中相同之定義* 即為 (請先閲讀背面之注意事項再填寫本頁) 本紙張尺度遑用中因國家楳毕(CNS)甲4規格(210x297公*) -9 - 209863 五、發明説明(8 在I a中R 2 在I b中R 1 在I c中R 1 在I d中R 5
與R 與R 與R
於I e中R
於I s中R 2各為A ; 2各為C Η 3 ; 2合併為C3 — C«伸烷基; 為未經取代或經0H取代之吡啶基, 嗒阱基,嘧啶基或吡哄基或經A取代 之酮二氫吡啶基或酮二氫嗒阱基; 為1一位置被甲基,乙基,異丙基或 笮基取代之6—酮基一1, 6—二氫 一 3 -嗒阱基; 為2—酮基一1, 2—二氫一1, 一 2—, _3—或一4一吡啶基或4一 酮基一1,4一二氳一3—吡啶基; 為1 一甲基一 2—酮基一 1,2 —二 氣一 4 一耻淀基; 於In中與R2各為CH3或合併為一 (CH2) 4 —
R (請先閲讀背面之注意事項再填寫本頁) 經濟部中央標準局兵工消费合作社印製 或-(C Η 2) 5 ; 為未經取代或經0Η基取代之吡啶基 ,嗒胼基,嘧啶基或嗒啶基或經Α取 代之酮二氫吡啶基或酮二氫嗒阱基, 及 與R9各為Η或CH3 , 與R 2各為C Η 3 ; 為1 一甲基一,1 一乙基一,1 一異 丙基一或1 一笮基一 6 —酮基一 1 , 本紙張尺度边用中國Η家猱準(CNS)甲4規格(210x297公*) -10 - 209863 五、發明説明(9 ) 6 氳一3—嗒阱基,及
於Ij中1^與112各為CH
R 為2 —酮基一1,2 —二重一1 一, 2 3—或一4_吡啶基,4 經濟部中央標準局β工消费合作社印製 ,一酮基一 1,4 一二氫-3 —吡啶基 或1一甲基一 2 —酮基一 1, 2 —二 氬一4一吡啶基,及 R 9為氫或甲基。 更好之化合物為式I —及I a —至I j -(相對於式 I及la至Ij),但其中各式之R3為Η, OH, OCHO或OCOCH3且R4為H,而特別是在式I 一 及I a <至I j >中,R3為OH且R4為Η之化合物。 再者,更好之化合物為式I 〃及la 〃至Ij 〃(相 對於式I及I a至I j ·但其中各式之R3與R*合併為 一鍵。 式 I, I', I",la 至 Ij, la'至 Ij'及 I a "至I j "之化合物為較好的,各式中另有 (a ) R β不為Η ,且 R 7 為 Η ; (b) R6不為Η且位於6_位置,且 R 7 為 Η ; (c) R* 為 N〇2 , CN, CHO, ACO, HOOC ,AOOC, ACOO, F , C 1 , B r , I ,CF3 , H2NCO, H2NCS 或 NHa 且 (請先閲讀背面之注意事項再填窝本頁) 裝. -訂- 線. 私紙張尺度边用中B困家標準(CNS) Ή規格(210x297公龙) -11 209863 A6 B6 五、發明説明 R 7 (d ) R β R 7 (e ) R 5 R 7 (f ) R 6 經濟部屮央標準局C5工消t合作社印製 R 7 (g ) R e R 7 (h ) R e R 7 (i ) R 6 R 7 (j ) R e R 7 式I , la 〃 至 I 好定義者為 (10) 為Η ; 為 NO? , CN, CHO, ACO, HOOC ,AOOC, ACOO, F, Cl, B r , I ,CF3 , H2NC0, H2NCS 或 NH* 且 位於6 —位置,且 為Η ; 為 Ν〇2 , CN, CHO, CHaCO, CH3〇OC, C2H5〇OC 或 CH3C〇0 且 為H ; 為 N〇2 , CN, CHO, CHaCO, CHaOOC, C2H3〇OC 或 CHaCOO 且 位於6 —位置,且 為Η ; 為Ν Ο 2或C Ν且 為Η ; 為Ν〇2或01^且位於6 —位置,且 為Η ; 為C Ν且 為Η ; 為CN且位於6 —位置,且 為Η 〇 I 一,I ",I a 至 I j , I a 一至 I j 一, j 〃之化合物及前述化合物中剩餘基圄具有較 更好,且其中Rs為CH3。 η 先 閲 背 面 之 注 意 事 項 再 填 寫 本 頁 本紙張尺度逍用中國S家楳準(CNS)甲4規格(210X297公货) -12 * 209863 A 6 B6 經濟部屮央標準局β工消费合作社印製 五、發明説明(11) 若未特別定義,則上述及下述中之R1至只〃及A如 式I中之定義。 此外本發明傜有關於製備如式I所示之喷衍生物的方 法,其特撳在於令式I之喷X、〇 七2 11 R1 其中 0 / \ X — Y為一 CH — CRe - 或一 CHE — CR3Re 一而 E 為Cl, Br,I或一反應性經酯化之OH基而 R1 , R2 , R3 , R* , R7與R*如式I中之定義 與式Μ化合物反應 Rs -NH-R9 I 其中R s與R 9如式I中之定義, 或是與式I化合物之反應性衍生物反應, 及/或令式I化合物,其中之R3為OH而R4為H,進 行脱水反應及/或將式I化合物中一或多値R3,R5, R?及/或R7基画轉變為另一R3 , R5 , R"及/或 R6
(請先《讀背面之注意事項再填寫本頁) 本紙張尺度边用中a Η家標準(CNS) Τ4規格(210X297公*} -13 - 〇 09863 Α6 Β6 經濟部中央標準局κχ工消合作社印製 五、發明説明(12) R7及/或將式I之鍮化合物以酸處理而轉變為其酸加成 鹽。 另外亦可以用此蓊中熟知之方法來製備式I化合物, 如文獻中所述的(如一些標準番籍H〇uben-Weyl,Metho-den der Organ i schen Chemie (Methods of Organic Chemistry) ,Geo rg-Th i eme Verlag. Stuttgart; Organic Reactions,John Wiley & Sons, Inc·,New York;及上 述專利申請案中),特別是那些利用已知且適於所述反應 之反應條件的方法。在本案中可使用此蕤中公知之變數, 此處不再詳述。 荐需要,起始物可於同處On situ)産生而不必自 反應混合物中單離出,而立刻進一步反應而得出式I化合 物。 較好將式I化合物與式Μ化合物反應,且較好於惰性 溶劑存在下及0至150°之溫度内反應,而製得式I化 合物。 0/ \ 式ϋ起始物其X — Υ為一 CH — CR* —(3, 4 — 琛氣咬)較好。 起始物I及Π —般為已知(例如比較DE — 0S 372626 1)。若為未知,可由此蕤中公知方法製得 (請先閲讀背面之注意事項再填窝本頁) % 本紙張尺度边用中國Β家樣準(CNS) 規格(210x297公¢) 14 - 209863 Μ 經濟部屮央標準局EX工消費合作杜印製 五、發明説明(13) 0/ \ 。因此式I起始物(一 X — Υ — = 一 CH-CR* —)可 由下法製得:2 —羥基苯乙酮(其式如 2- H0-RtfR7CeH2-C0CH3)與酮類(其式如 R2 — CO — R2 )反應而製得對應之式IVa4—喷酮 R61、 Y R2 R1 . / 若需要,與化學式如A — CHO之醛類縮合(A = Ci — Ce烷基)而得出式IVb之3 —次烷基_4 一嗅酮,再 還原(如以NaBH* )得出式IVc之喷酵,脱水後, 如利用對甲苯磺酸而得出式IVd之喷烯,再氣化,如以 3— 氣過苯甲酸。最後之氣化作用可由數値步驟來完成, 如首先於水性溶液利用N_溴丁二醛亞胺與之反應並以鐮 ,如氫氣化鈉溶液,去除生成之HBr而製得式IVe之 溴代酵。 式IVd之咬烯亦可自下法製得:由式 2-H0-RtfR7CeH2-CH0的水揚基醛與式Ri-CO-CU*的酮 縮合而得出式2-H〇-ReR7CsH2-CH-CRs-C〇-R2的羥基酮, 再與式R2— L i之有機鋰化合物反應,随後水解得出如 式a-HO-WCeKH-Cir-CWOH之二酵,然後將之脱 (請先閲讀背面之注意事項再填窝本頁) 本紙張尺度边用中a困家樣準(CNS)甲4規格(210X297公釐) -15 - 209863 經濟部中央標準局β工消费合作社印製 五、發明説明(14) 水琛化而製得。 式I[化合物(-X-Y- — CHE-CR3Re -)中可能之★反應 性酯化之0H基画〃,特別是烷基磺酸(其烷基含1至6 値碩原子)之酯或是芳基磺酸(其芳基含6至10個碩原 子)之酯。道些化合物可由式IVc之4一喷酵與無機酸 齒化物,如 PC 交 3 , PBr3 , S0Ci?2 或 SOBra 反應而得,或是由式I Vc喷酵與磺醛氰,如甲磺酵《或 對甲苯磺酵氣,反應而得。 適合之式I的反應性衍生物為其對應之鹽類,如鈉鹽 或鉀鹽,其亦可同位置産生。 在驗存在下反應是適合的。合適的鐮有,如鹼金屬或 鹼土金屬之氳氣化物,碩酸鹽,酵鹽,氳化物及氨化物, 如 NaOH, KOH, Ca (OH) 2 , Na2C〇3, K2C〇3,甲醇鈉或甲酵納,乙酵鈉或乙酵鉀或第三丁醇 鈉或第三丁醇鉀,NaH, KH, CaH2, NaNHi KNH2 ,此外尚有有機齡,如三乙胺或吡啶,其可過置 使用並同時作為溶劑。 合適之惰性溶劑為,特別是,酵類,如甲酵,乙醇, 異丙酵,正丁醇或第三丁醇;_類,如二乙醚,二異丙醚 ,四氫呋喃或二氣陸困;乙二酵醚,如乙二酵單甲醚或乙 二醇單乙醚(甲基乙二醇或乙塞乙二醇),乙二酵二甲醚 (diglyme);酮類,如丙酮或丁酮;睛類,如乙睛;硝 基化合物,如硝基甲烷或硝基苯;酯類,如乙酸乙酯;醛 胺,如二甲基甲醯胺(DMF),二甲基乙醛胺或六甲基 (請先閲讀背面之注意事項再填窝本頁)
T 象 本紙張尺度边用中國a家«準(CNS)甲4規格(210x297公 -16 - ;〇9863 Ϊ% 經濟部中央標準局员工消费合作社印製 五、發明説明(15) 磷醛胺;亞砚類,如二甲基亞硯(DMSO);氮碩氫化 合物,如二氣甲烷,氯仿,三氯乙烷,1, 2—二氛乙院 或四氯化碩;烴類,如苯,甲苯或二甲苯。另外這些溶劑 之混合物亦為合適者。 0/ \ 琛氣化物I (X — Y — = CH — CR8 —)亦可同位 置製得,例如將對應之溴代酵IVe以齡作用。 一持別好之步驟包含:利用醇類(如乙酵)作為溶劑 而後加入有機驗(如m啶),令反應混合物沸騰約〇. 5 至2 0小時。 式I化合物且其R3 = OH而R4 = H可用脱水劑處 理而轉變為R3與R4合併為一鍵之式I化合物。其偽於 ,例如,上述溶劑中(如DMSO)及0至150°之溫 度,經上述鹼(如NaH)作用而進行。 另外,式I化合物中一値或多個R3 , R5 , R6及 /或R7基圃可被轉換成另外之R3 , Ra, Re及/或 R 7 〇 例如,可以將Η原子以齡化作用換為齒素原子,或是 將Η原子以硝化作用換為硝基及/或將硝基還原成胺基及 /或將胺基或羥基院化或醛化及/或將氰基轉變為羧基( 例如於水/甲醇中以HC5於20— 1 00°反應)或將 氰基轉變為甲醯基(如於水/醋酸/吡啶及磷酸鈉存在下 以Raney Ni處理)或將氖基轉變為胺甲醯基(如於第三 (請先閲讀背面之注意事項再填寫本頁)
T 本紙張尺度遑用中困B家樣毕(CNS)甲4規格(210X297公釐> -17 - 209863 A 6 B6 經濟部中央標準局员工消费合作社印製 五、發明説明(16) 丁酵中以KOH處理)或將氡基變為胺硫甲醯基(如於吡 啶/三乙胺以H2S處理)及/或將一 CO — NH —基轉 變為一 CS — NH —或一 C (SH) = N —基(如於甲苯 中以PaSs或Lewesson試劑處理)。 硝化作用傜於習知條件下進行,如利用滠HN〇3及 濃H2S〇4之混合物於0至30°之溫度。若與R7 取代基至少有一値為霣負性基圄,如CN或N〇2 ,此硝 化作用大部分發生在R5上;另外之情況下則硝基一般會 在R5或咬琛上發生而製得混合物。 同法應用於鹵化作用,如於一種習用情性溶劑中,〇 至3 0°之溫度下利用氯或溴元素來達成。 藉由烷化劑之處理一级胺基或二级胺基及/或0H基 可被轉變為對應之二级或三级胺基及/或烷氣基。合適之 烷化劑為,例如,式A — Ci?, A — Br或A — I之化合 物或對應之硫酸或磺酸酯,如氮甲烷,溴甲烷或碘甲烷, 二甲基硫酸或甲基對甲苯磺酸酯。此外,如可將一値或兩 個甲基藉由甲醛及甲酸存在下引入。烷化反應較好於上述 惰性溶剤(如DMF)存在或不存在時及約0°至 120°之溫度下進行,而其中可有催化剤存在,如第三 丁醇納或NaH等鹼類。 適合將胺基或羥基醯化之醯化劑較好為羧酸之鹵化物 (如氣化物或溴化物)或其酸酐,如醋酸酐,丙醯氯,異 丁醯溴,甲酸/乙酸酐與苄醯氯。此外可於醯化作用中添 加鹼,如吡啶或三乙胺。醛化作用較好於惰性溶劑存在或 (請先閲讀背面之注意事項再填窝本頁} 裝- 订- 線- 本紙張尺度边用中國B家標準(CNS) T4規格(210X297公¢) -18 - 2098G3 A 6 B6 經濟部中央標準局A工消费合作社印製 五、發明説明(17) 不存在或過置三级齡(如吡啶或三乙胺)中於約〇°至约 160°間之溫度進行,較好在20°至120°間;該 情性溶劑有烴類,如甲苯,睛類,如乙腌,醛胺類,如 DMF。而甲醛化可利用甲酸及吡啶存在下來進行。 式I之驗.可利用酸轉變成對應酸加成鹽。而可以得出 生理學上可接受鹽類之酸類待別適於此反應。因此,可使 用無機酸,如硫酸,硝酸,氫鹵素(如氳氣酸或氫溴酸) ,磷酸(如正磷酸),胺基磺酸,尚有有機酸類,特別是 脂族,環脂族,芳腊族,芳族或異琛之單價或多價的羰酸 ,磺酸或硫酸,例如甲酸,乙酸,丙酸,第三丁基酸,二 乙基醋酸,丙二酸,丁二酸,庚二酸,反丁烯二酸,順丁 烯二酸,乳酸,酒石酸,羥基丁二酸,苯甲酸,水揚酸、 2 —或3 —苯基丙酸,掙樣酸,蕕萄糖酸,抗壞血酸,菸 驗酸,異菸鹼酸,甲磺酸,乙磺酸,乙二磺酸,2 —羥基 乙磺酸,苯磺酸,對甲苯磺酸,某磺酸,棻二磺酸及十二 烷基硫酸。而生理上不可接受之酸的鹽,如苦味酸鹽,可 用來純化式I化合物。 式I化合物可具有一個或多値對掌中心,因此在其製 備過程中可以消旋物製得;或是若以光學活性起始物開始 ,則可得到光學活性形式。若化合物具有二個以上之對掌 中心,則在合成中會以消旋物之混合物製得,自此混合物 可單離出純的消旋物,如以惰性溶劑再結晶。所以,例如 R2 = R* , R3 = 0H且R4 = H之式I化合物,其具 .有兩個對箪中心;然而在將化合物I與I反應時,幾乎只 (請先閲讀背面之注意事項再填窝本頁) 裝* 訂- 線. 本紙張尺度边用中《國家標準(CNS)甲4規格(210x297公;it) -19 - 209863 經濟部屮央樣準沿兵工消费合作社印製 五、發明説明(18) 有一種消旋物佔大多數,且其R3 = OH與R5RSN =取 代基位於反式位置。若需要可將所得消旋物以此籙公知之 方法利用機械、化學或生化的方式分離成其鏡像異構物。 因此由消旋物與光學活性解析剤反應而得到非鏡像異構物 。對式I鹸性化合物之合適的解析劑為,例如光學活性酸 ,如D—或L一之酒石酸,二笮醯基酒石酸,二乙醛基酒 石酸,樟腦酸,樟腦磺酸,苯乙酵酸,羥基丁二酸或乳酸 。原醇類(式I其R3 = OH)尚可經酯化而後解析,其 傺藉對掌性醯化劑來達成,如上述酸類,特別是(+ ) — 或(一)一樟腦酸或(+ ) —或(一)一樟腦一 10 —磺 酸,或是D —或L 一甲笮基異氰酸酯(比較EP — A1 — 1 20, 428)。而非鏡像異構物之不同形式可藉此藝 公知方式分離,如分段結晶,至於式I之鏡像異構物可自 此非鏡像異構物以此蕕公知方式來釋出。此外以光學活性 支持物質進行層析而解析出鏡像異構物。 式I化合物及其生理學上可接受鹽類可用來製造藥學 组成物,待別是以非化學之方式。就此而論,其僳與至少 一種固體,液體及/或半液醱賦形劑或佐藥而且若有需要 ,再混以一種或多種另外之活性化合物以形成適用之形式 Ο 此外本發明亦有關於一些至少含有一種式I化合物及 /或一種其生理學上可接受鹽類之試劑,持別是藥學組成 物0 這些藥學組成物可作為人類或獸類之用藥。合適之賦 (請先閲讀背面之注意事項再填窝本頁) fr 象 本紙張尺度遑用中國β家楳準(CNS)甲4規格(210X297公*) -20 - 209863 A 6 B6 經濟部屮央楳準局Μ工消費合作社印製 五、發明説明(19) 形劑為適於經腸(如口服),非經腸或局部施予之有機或 無機物質且其不與該新穎化合物作用者,如水,蔬菜油, 苄基酵,聚乙二醇,甘油三乙酸酯,明膠,磺水化合物, 如乳耱或澱粉,硬脂酸鎂,滑石,羊毛脂或凡士林。錠, 包衣錠,膠囊,漿,酊或滴藥特別適合經口投予,栓剤則 特別用於經直腸施予,而溶液(較好為油性或水性溶液) 及懸浮液,乳液或植入劑特別適於以非經腸方式投予,膏 ,霜,糊,藥水,膠,噴霧劑,泡沫,氣溶膠,溶液(如 醇類溶液,如乙酵或異丙醇,或是乙腈,DMF,二甲基 乙醯胺,1 , 2 —丙二酵或其混合物及/或再混有水)或 粉末特別適於局部施用。此新穎化合物亦可經真空乾燥, 而後用於,如,製備注射製劑。微脂粒製劑亦待別適於局 部施用。上述製劑可經殺菌及/或可含有佐藥,如潤滑剤 ,防腐劑,安定劑及/或溼潤劑,乳化劑,影辑滲透壓之 鹽類,缓衝物質,色素及調味料及/或香料。若需要亦可 含有一種或多種另外之活性化合物,例如一種或多種維生 素。 式I化合物及其生理學上可接受之鹽類可施用至人類 或動物中,特別是哺乳動物,如猴,狗,貓,大鼠或小鼠 且可用於治療人醱或動物鼸之失調病症,持別是治療及/ 或預防心血管条統之擾動,特別是代償機能衰敗之心官能 不足,心絞痛,心律不整,末梢或腦部小管失諏,及與高 血壓有關之疾病狀態,此外尚有與非脈管肌条變化有蘭之 失調病症,如氣喘或尿失禁。 (請先閱讀背面之注意事項再填寫本頁) 本紙張Κ度边用中國困家《準(CNS)甲4規格(210X297公釐) -21 - 209863 經濟部中央標準局貝工消费合作社印製 玉、發明説明(20) 就此而言,本發明之物質通常以已知抗絞痛或低血壓 劑(如n i corand i 1或cromaka 1 i m)之類似方式施用,較 好約0. 01至5呢之劑置,待別是每剤量單位0. 02 至◦. 5聪。而毎天的劑量較好在毎公斤髏重約 0. 0001至0.1之間,特別是0. 0003至 0. 01呢。然而毎位病人之持定劑量取決於多種因素, 如使用化合物之效力,年齡,體重,健康之一般狀態,性 別,食物,時間,施藥途徑,排泄速率,藥品之组合,欲 治療疾病的嚴重性。較好以口服施蕖。 此外,式I化合物及其鹽類尚可用於,特別是局部用 藥而治療簇狀禿髮。為此目的,適於頭皮及上述局部治療 的藥學组成物僳被用來達成此目的。其含有約0. 005 至10wt%,較好0. 5至3wt%之至少一種式I化 合物及/或至少一種其鹽類。另一方面,谊些化合物可以 類似於W0 88/00822之方式來對抗禿髮。 下述實施例中,"習用單離純化方式"指將反應混合 物以水處理後以有機溶劑(如乙酸乙酯)萃取,分離出有 機相以硫酸納乾燥,而殘留物再以管柱層析及/或結晶而 純化。 上述及下述之溫度皆為t:。 實施例1 於25。時將2. 0g2, 2 —二甲基一 3, 4 —琛 氣基一 6 —氰基咬la ")加入1. 2g3 —胺基一 (請先閲讀背面之注意事項再填窝本頁) 本紙張疋度边用中困B家標毕(CNS)甲4規格(210x297公釐) -22 - 附件1Α i第 80109502
修捕專利申請案中文說明書修正I B6 民國81年12月修正 五、發明説明(21) 1 一甲基一 1,6 —二氫塔阱一 6 —酮及0.3g NaH (80%強度)於50mL二甲基亞砠(DMSO )之混合物,然後將所得混合物攪拌4小時。以習用單離 純化方式處理並以管柱層析純化(以乙酸乙酯/甲酵沖提 )而得出少置2, 2 —二甲基一4 一(1 一甲基一 1, 6 一二氣一 6 —嗣一 3 —堪哄胺基)一 6 —1R基一 3 —咬嫌 (其並未純化),而後接著為主要産物2—二甲基一 4一 (1一甲基一1, 6—二氩一6—酮一3—塔阱胺基 )—6 —氰基_3 —喷醇,m. p. 117— 119°。 同法得到下述: 由3—胺基一1 _书基一 1 , 6 —二氫塔哄一 6 —酮及★ la": 2,2 —二甲基一 4 一 (1 一韦基一1,6 —二 6—酮一3—塔阱胺基)_6-氣基一3—暌酵, m. p. 233-236° ; 由3 — N —甲胺基一 1 一甲基一1, 6 —二氫堪哄一 6 — 酮及"I a ": 2,2 —二甲基一 4 - (1 一 甲基一 1,6 —二氢一 6—酮一3—嗒阱一N—甲胺基)~6—氰基一3—喷醇 ,m. p. 242-244° ; 由3_胺基一1一異丙基一1, 6~二氫嗒阱一6—酮及 々I a々: 2, 2—二甲基一4一 (1一異丙基一1, 6—二氫 一6—酮一3_塔阱胺基)一6—氡基一3-喷醇, (請先閲飧背面之注意事項再填寫本^ .丨装· 訂. 經濟部中央標準局R工消费合作社印製 衣纸張尺度適用中國囿家愫準(CNS)甲4規格(210 X 297公笼) ~ Z0 - 81.9.25,000 2〇9Bti^ A6 B6 絰濟部中央標準局员工消費合作杜.印製 五、發明説明(22 ) — :二。 m . P . 2 2 3 - 2 2 5 ° ϊ 由3—胺基一1一乙基一1, 6—二氫嗒阱一6—酮及Λ la": 2,2 —二甲基一 4 一 ( 1 一 乙基一 1,6 -二氫一 6—酮一3—塔阱胺基)一6—氰基一3—喷醇, m. P. 225 — 228° ; 由3—胺基一1一甲基一1, 6—二氬嗒阱一6—酮及2 ,2,3 —三甲基一 3,4 一環氣基一 6 —氣基喷: 2, 2, 3—三甲基一4一 (1一甲基一1, 6-二 氫一 6—酮-3 -嗒阱胺基)一 6 —氰基一 3 —暌醇, m. p. 258-260° ; 由3—胺基一1一甲基一1, 6—二氫嗒阱一6—酮及2, ,2 —二甲基一 (3S, 4S) —環氣基一 6 —氰基暌: 2, 2 —二甲基 _ (4R) - (1 — 甲基一1, 6 — 二氩一 6 —酮一 3 —嗒阱胺基)_ 6 —氰基一(3 S ) — 暌醇,m· ρ· 177-18 0° ; 由4 —胺基一 1 一甲基一 1, 2 —二氫吡啶一 2 —酮及2 ,2—二甲基一 (3S, 4S) —環氧基一6—氣基喷: 2,2 -二甲基一 (4R) — (1 一甲基一1, 2 — 二氫一 2 —酮一 4 一吡啶胺基)一 6 _氰基一 (3 S ) — 喷醇,m. ρ· 283 — 285°。 奮施例2 將1. lg 1—胺基一 1, 2 —二氫吡啶一 2 —酮 與 3 . 1 g 2,2 , 3 —.」三、早基.*一《3..,4 一環氣基一 6 (請先H-讀背面之注意事項再填窝- —装. 訂. 本紙張又度適用中國S家橒準(CNS)甲4規格·(210 X 297公贷) -24 - 81.9.25,000 209B63 A6 B6 五、發明説明(23 ) 一氯基嗅加熱至熔黏,在此溫度攪拌8小時。殘啻物以管 柱層析(二氯甲烷/乙酸乙酯;矽騮)純化。得出2, 2 ,3—三甲基一4一 (1, 2—二氳一2 一 1 一 .耻淀 胺基)—6 -.氣基—3 - 喷醇,.m.p ·1 84 — 1 87。 。由1 一胺基一1,2 —二氫Bit淀一 2 —酮及、、Ea "同 法可得: 2, 2-二甲基一4一 (1, 2—二氬一2—酮一1 ―妣淀胺基)_6_氣基一 3 —喷酵,111.口.202 — 2 0 4 0 〇 奮掄例3 請 先 閲 讀 背 面 之 注 意 事 項 再 填 寫 裝 經濟部中央標準局员工消費合作社印製 將0· 5mL三乙胺加入1.lg 3—胺基_1, 6 -二氫吡啶-6-酮與2. Og、' Ia "於50mL乙 醇之溶液,然後令此混合物沸騰2小時。以習用單離純化 方式得出2,2—二甲基一 4 一 (1,6 —二氣一 6—嗣 ~3 —吡啶胺基)_6 —氮基一 3 —暌醇· m. p. 2 8 5 - 2 8 7 0 〇 由3 —胺基一 1,2 —二氫吡啶一2 —酮與★ Ha " 同法可得: 2, 2 —二甲基一4 - (1,2-二氫一2 —酮一3 一吡啶肢基)一 6 —氰基一 3 —喷醇,m. p. 278 — 2 8 0 0 〇 奮施例4 以類似實施例3之方式,由3-胺基一 1,4 一二氫 吡啶一 4 一酮之H C 2鹽與a 1 a 〃而製得2 , 2 — 甲 訂 紙張尺度適用中國國家櫺準(CNS)甲4规格(210 X 297公穿) -25 - 81.9.25,000 A6 B6 098^3 五、發明説明(24) 基—4 一(1· 4 一二氣一 4 —鬭一 3 -耻陡胺基)一 6 一氯基一 3 —喷酵,鹽酸鹽,m.p.268 — 270。。 奮施例5 於20°令l.lg 3 — N —甲胺基一1 一甲基一 1,6 —二氫嗒阱一 6 —酮,2. Og* la 々與0. 3 g NaH (80%強度)於50mL DMS0中攪拌 6小時而後以習用單離純化方式處理而得出2, 2—二甲 基一 4 一(1 一甲基一 1, 6 —二氳一 6 —酮一 3 —塔哄 基一 N —甲胺基)一 6 —氣基一 3 —喷烯,m. ρ· 134 — 136° ,以及少量2, 2 —二甲基一4 一(1 一甲基一1, 6—二氫一6—酮一3—嗒阱基一N—甲胺 請 先 閲- 讀 背 面- 之 注 意 事 項 再 填 寫 Τ 裝 基)一 6_瓴基一 3 —喷醇, m . p 2 4 2 - 2 4 2 ;二者可用矽膠層析(以乙酸乙酯與少置甲醇之混合物沖 提)而軽易地分離。 由4一胺基一1一甲基一1, 2—二氫社症一2—酮 與'λ I a "同法可得: 2, 2—二甲基一4一 (1一甲基一1, 2—二氫一 2 —酮一 4 ~吡啶胺基)一6 一氰基一 3 一喷烯,m.p. 200-2020。 奮施例6 令2. 〇g 2, 2—二甲基一4一 (1一甲基一1 ,6 — 一氮一6 -酮一 3 -塔阱胺基)一 6_氰基一 3 — 喷醇於2OmL醋酸酐中沸騰2小時。以習用單離純化方 式處理得出1 · 2 二甲基一 3 —乙醒氧基一 4 一 ( j <-— 訂 經濟部中央櫺準居興工消费合作社印製 本纸張尺度ία用中國國夂標遵(CNS)甲4規格(210 X 297公货) _ 26 _ 81.9.25,000
附件2A 第80109502 號專利申諳案中文説明窨修正頁 民國81年6月修i
£
U
五、發明説明(25) 甲基一1, 6—二氣一6—_一3—塔哄胺基)一6—氰 基—3 — 喷,m. p. 110 — 112°。 下述實施例係有關於包含式I化合物或其生理學上可 接受鹽類之藥學组成物:
審掄例A 錠片 將 lg 2, 2 —二甲基一 4 一 (1 一 甲基一 1,6 一二氣一6—嗣一3-塔阱胺基)一6—银基一3—喷醇 ,4kg乳糖,1. 2kg馬鈐薯澱粉,0. 2g滑石與 0. lkg硬脂酸鎂之混合物以習用方式壓製成錠片,使每 錠包含0· lmg活性化合物。 奮施例B 包衣錠 用實施例A壓製錠片,而後以習用方式將蔗糖,馬鈴 薯澱粉,滑石,阿拉伯樹膠及色素形成之包衣包覆。 奮旃例Ο 膠囊 (請先閲讀背而之注意事項#堝寫本頁) 装· 訂- 線- 經濟部中央標準局貝工消費合作社印製 以習用方式將lkg 2, 2, 3 —三甲基一 4 一 (1 一甲基一1, 6—二氫一6—酮一3—嗒阱胺基)一6— 氣基一3—咬醇裝熵入硬明醪膠囊,而使毎傾膠囊包含 〇. 5mg活性化合物。 安祖 0g 2, 2—二甲基一4一 (1一甲基一1, 6 本紙張疋度遠用中國國家«準(CNS)甲4規格(210X297公*) 81. 2. 20,000 27 - 經濟部屮央標準局貝工消费合作社印製 五、發明説明(26) 一二氣一6—嗣一3-塔阱胺基)一6-氰基一3—喷醇 於70升1, 2—丙二醇之溶液以二度蒸蹯之水配成 100升,殺菌過濾,將此溶液裝入安瓿,並以滅菌方式 密封此安瓿。毎掴(安瓿包含0. 1 mg活性化合物。 以類似方法可裂得包含一種或多種其他之式I化合物 及/或其生理學上可接受之鹽類的錠片,包衣錠,膠囊或 安瓿。 (請先閲讀背面之注意事項再填窝本頁) -裝- 訂- 線- 本紙張尺度遑用中鷗B家標準(CNS)甲4規格(210 x297公 -28 -
Claims (1)
- A7 B7 C7 D7 π、申請專利範園 附件二Α 第80109502號專利申請案中文申請專利範豳修正本民國81年I2月修正 1. 一種如式I所示之喷衍生物, r9 - R5 /ri I R3 r2 (請先閲讀背面之注意事項再填窝本頁) 裝 «濟部中央櫺準扃貝工消费合作杜π« 其中 R J 與 R 2 R 3 R 4 R 3 與 R 4 R 9 - ^ R r R 5 A Ac 及其鹽類。 各為A » 為Ο H或0 A c, 為Η , 合併亦為一個鍵, 為Η或A , 為酮二氫吡啶基,酮二氫嗒阱基,且上述基 画僳未經取代或經A單取代, 為C N, 為C : 一 C 5烷基,而 為乙醛基, 2 . a ) 2,2 —二.甲基 一一 ',( 1 一 甲基一 ’1,6 訂 夂紙張尺度適用中國國家標準(CMS)甲4規格(210 X 297公釐) 一 1 一 8L9.!〇,〇〇〇 A7 B7 C7 D7 六、申請專利範園 (請先閲讀背面之注意事項再填窝本頁> —二氫一 6 —酮一 3 —嗒阱胺基)一 6 基一 3 —喷酵, b)反一 3, 4 —二氬一4 — (1, 6 —二氫一 1 一甲基一 6 —酮一 3 — !§:阱胺基)一 2 , 2, 3—三甲基一6—氰基一3—喷醇; c ) (411,33)-2,2—二甲基一4一( 1一甲基一1, 6—二重一6—嗣一3—塔 阱胺基)一6—氰基一3—喷醇; d) 2,2 —二甲基一 4 一〔N — (1 一 甲基一 6_酮一 3 —嗒阱基)一 N —甲胺基〕一 6 一氰基一3—喷醇。 3· —種製備如申請專利範圍第1項所定義的式I咬 衍生物之方法,其特徴在於令式I之喷 I R- R, 煖 濟 部 中 央 櫺 準 局 貝 3. 消 费 合 作 社 印 * 其中 0 X—Y為一CH—CH—而 E 為C1, Βγ,Ϊ或反應性經fit化之OH基及 g I R2, R3與如式I中所給之定義; 本纸張尺度適用中國圃家捸準(CNS) P·*规格(2】〇>< 297公釐) -2 81.9,10,000 A7 B7 C7 D7 六、申請專利範園 與式I化合物反應 R5 -NH-R9 I 其中R5與R3如同式I中所給之定義, 或與式Π化合物之反應性衍生物反應; 及/或此方法之特徽為令式I化合物,其R3為QH,進 行脱水及/或將式I化合物中一或多値R3,R5 及/或 R6基圃轉變為另一 R3,R5及/或R6及/或將式I 之鹼化合物以酸處理而轉變為其酸加成鹽。 4. 一種用於治療高血壓之藥學組成物,其含有至少 一種如申請專利範圍第1項之式I所示之喷衍生物及/或 一種其生理學上可接受鹽類。 5. 如申請專利範圍第1項之式I所示之喷衍生物, 其係用於控制疾病。 .* T (請先閲讀背面之注意事項再填窝本頁| 丨裝| 訂· .繁, 經濟部中央櫺準扃Λ工消費合作社印製 本紙張尺度適用中國围家標準(CNS)甲4規格(210 X 297公踅) -3 - 81.9.10,000 附件一A : 第80109502號專利申請充藥 民國81年6月呈化飾 πι·ρ· rc] R3 R4 RS R8 R分 血壓降低 1) [mm HgJ 鬆弛作® 2) ICso [mol/l] 3) 扣ol/l〕;mV 17/18 117-119 OH H 1 一甲基7" 6 —嗣一 Η Η -131 2 X 10*e 10~7 ; 29 17/29 242-244 OH H 3—pz. 1-TO-6-S0-L6 Η he -121 6 X 10-7 i〇-s ; 31 17/34 223-225 OH H Η Η -106 6 X io-7 10-5 ; 30 18/2 225-228 OH H Η Η -135 1 X 10-7 10-7 ; 31 18/7 258-260 OH H He Η -155 2 X 10·8 l〇-7 - 34 18/12 177-180 OH H —3—pz· 1 二^基一 嗣一1^6 Η Η -107 5 X io-9 10-7 ; 28 —二氮一3 — p z. 18/37 285-287 OH H Η Η -68 5 X l〇-6 io-4 ; 25 19/27 110-112 Olk H 1 6 酮 1,6 Η Η -128 6 X JL0-6 —二氨一 3一 pz. 縮寫:pz.=塔π井基 ;He =甲基 上面各種不同的測試像根據説明書(中文第5頁,ϋ第 2頁)所述方法來進行。 1) 血蹈降低活性(SHR, 口服投于給老鼠) 劑量單位:1 ms/kg體重 · . 2) 鬆弛作用:對分離的血管因拮抗劑導致收縮之抑制( 雜之冠狀動脈;I Csc«值) 3) 極化過度作用(以兔子分離出的肺動脈測試);△ mV :相對膜電位的改變。
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4038752A DE4038752A1 (de) | 1990-12-05 | 1990-12-05 | Chromanderivate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW209863B true TW209863B (zh) | 1993-07-21 |
Family
ID=6419627
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW080109502A TW209863B (zh) | 1990-12-05 | 1991-12-03 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US5238937A (zh) |
| EP (1) | EP0489327B1 (zh) |
| JP (1) | JPH04300880A (zh) |
| KR (1) | KR100220002B1 (zh) |
| AT (1) | ATE166649T1 (zh) |
| AU (1) | AU645373B2 (zh) |
| CA (1) | CA2056845A1 (zh) |
| CZ (1) | CZ280911B6 (zh) |
| DE (2) | DE4038752A1 (zh) |
| DK (1) | DK0489327T3 (zh) |
| ES (1) | ES2119751T3 (zh) |
| GR (1) | GR3027561T3 (zh) |
| HU (1) | HU215518B (zh) |
| IE (1) | IE914213A1 (zh) |
| PT (1) | PT99688B (zh) |
| SK (1) | SK279095B6 (zh) |
| TW (1) | TW209863B (zh) |
| ZA (1) | ZA919573B (zh) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5387587A (en) * | 1986-12-23 | 1995-02-07 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Chroman derivatives |
| US5837702A (en) * | 1993-10-07 | 1998-11-17 | Bristol-Myers Squibb Co. | 4-arylamino-benzopyran and related compounds |
| US5719155A (en) * | 1993-11-10 | 1998-02-17 | Japan Tobacco Inc. | Chroman derivative and pharmaceutical use thereof |
| US5612370A (en) * | 1995-06-07 | 1997-03-18 | Bristol-Myers Squibb Company | Phenylglycine and phenylalaninen amido benzopyran derivatives |
| US5869478A (en) * | 1995-06-07 | 1999-02-09 | Bristol-Myers Squibb Company | Sulfonamido substituted benzopyran derivatives |
| US5629429A (en) * | 1995-06-07 | 1997-05-13 | Bristol-Myers Squibb Company | Process for preparing 4-arylamino-benzopyran and related compounds |
| US5612323A (en) * | 1995-06-07 | 1997-03-18 | Bristol-Myers Squibb Company | Phosphinic ester substituted benzopyran derivatives |
| KR20070003349A (ko) * | 2005-07-01 | 2007-01-05 | 한 성 육 | 가설 철도교용 체결장치 |
| EP1940516A2 (en) | 2005-09-01 | 2008-07-09 | Janssen Pharmaceutica, N.V. | Benzopyran and pyranopyridine derivatives as potassium channel openers |
| KR20250038282A (ko) | 2023-09-12 | 2025-03-19 | 한국철도기술연구원 | 탈부착 가능한 경사부재를 구비한 복합재료 침목용 레일 고정장치 및 그 시공방법 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3835011A1 (de) * | 1988-10-14 | 1990-04-19 | Merck Patent Gmbh | Chromanderivate |
| FR2615191B1 (fr) * | 1987-05-16 | 1991-01-11 | Sandoz Sa | Nouveaux benzo(b)pyrannes et pyrannopyridines, leur preparation et leur utilisation comme medicaments |
| AU628331B2 (en) * | 1988-05-06 | 1992-09-17 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Chroman derivatives |
-
1990
- 1990-12-05 DE DE4038752A patent/DE4038752A1/de not_active Withdrawn
-
1991
- 1991-11-25 ES ES91120050T patent/ES2119751T3/es not_active Expired - Lifetime
- 1991-11-25 DK DK91120050T patent/DK0489327T3/da active
- 1991-11-25 AT AT91120050T patent/ATE166649T1/de not_active IP Right Cessation
- 1991-11-25 EP EP91120050A patent/EP0489327B1/de not_active Expired - Lifetime
- 1991-11-25 DE DE59108997T patent/DE59108997D1/de not_active Expired - Fee Related
- 1991-11-29 AU AU88313/91A patent/AU645373B2/en not_active Ceased
- 1991-12-02 KR KR1019910021972A patent/KR100220002B1/ko not_active Expired - Fee Related
- 1991-12-03 TW TW080109502A patent/TW209863B/zh active
- 1991-12-03 CA CA002056845A patent/CA2056845A1/en not_active Abandoned
- 1991-12-04 CZ CS913674A patent/CZ280911B6/cs not_active IP Right Cessation
- 1991-12-04 IE IE421391A patent/IE914213A1/en unknown
- 1991-12-04 HU HU913797A patent/HU215518B/hu not_active IP Right Cessation
- 1991-12-04 US US07/802,093 patent/US5238937A/en not_active Expired - Fee Related
- 1991-12-04 JP JP3357437A patent/JPH04300880A/ja active Pending
- 1991-12-04 SK SK3674-91A patent/SK279095B6/sk unknown
- 1991-12-04 ZA ZA919573A patent/ZA919573B/xx unknown
- 1991-12-04 PT PT99688A patent/PT99688B/pt not_active IP Right Cessation
-
1998
- 1998-08-04 GR GR980401745T patent/GR3027561T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE4038752A1 (de) | 1992-06-11 |
| AU8831391A (en) | 1992-06-11 |
| KR100220002B1 (ko) | 1999-09-01 |
| PT99688B (pt) | 1999-05-31 |
| HU913797D0 (en) | 1992-02-28 |
| DK0489327T3 (da) | 1999-03-22 |
| ES2119751T3 (es) | 1998-10-16 |
| DE59108997D1 (de) | 1998-07-02 |
| PT99688A (pt) | 1992-10-30 |
| EP0489327B1 (de) | 1998-05-27 |
| EP0489327A1 (de) | 1992-06-10 |
| HUT62000A (en) | 1993-03-29 |
| ATE166649T1 (de) | 1998-06-15 |
| US5238937A (en) | 1993-08-24 |
| IE914213A1 (en) | 1992-06-17 |
| GR3027561T3 (en) | 1998-11-30 |
| ZA919573B (en) | 1992-08-26 |
| KR920012073A (ko) | 1992-07-25 |
| CA2056845A1 (en) | 1992-06-06 |
| HU215518B (hu) | 1999-01-28 |
| CZ280911B6 (cs) | 1996-05-15 |
| CS367491A3 (en) | 1992-06-17 |
| AU645373B2 (en) | 1994-01-13 |
| JPH04300880A (ja) | 1992-10-23 |
| SK279095B6 (sk) | 1998-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2996708B2 (ja) | 複素環式誘導体、その製造方法および前記誘導体を含有するロイコトリエン誘因性疾患または症状の治療に用いる薬理学的組成物 | |
| FR2727682A1 (fr) | Nouveaux derives de 3,5-dioxo-(2h,4h)-1,2,4-triazines, leur preparation et leur application a titre de medicament | |
| JPS626703B2 (zh) | ||
| TW209863B (zh) | ||
| JPH02273673A (ja) | 複素環式の環状エーテル、その製造法、および該化合物を含有するロイコトリエン調停された疾病または医学的症状に使用するための製薬学的組成物 | |
| JPH02268158A (ja) | 複素環式シクロアルカン、その製造方法および該シクロアルカンを含有する、ロイコトリエン仲介の疾病または症状に使用するための医薬組成物 | |
| US5217977A (en) | Heterocyclic cycloalkanes | |
| TW210337B (zh) | ||
| US4375479A (en) | Indanyl derivatives and use | |
| JPH04270285A (ja) | ピラゾロピリミジン系メバロノラクトン類 | |
| JPH02172973A (ja) | テトラリン誘導体 | |
| JPH02145584A (ja) | クロマン誘導体 | |
| JPH05117273A (ja) | 医薬化合物 | |
| JPH1067749A (ja) | キサンテン及びアクリジン誘導体、並びにその使用 | |
| EP0257616A2 (en) | Dihydropyridine derivates and pharmaceutical composition thereof | |
| JPS59512B2 (ja) | ピラゾ−ル −5− オンカゴウブツ ノ セイゾウホウホウ | |
| JPH0337549B2 (zh) | ||
| US4886819A (en) | Dihydropyridine derivatives and pharmaceutical composition thereof | |
| WO1991016323A1 (fr) | Derives du naphtosultame antagonistes de la serotonine, leur preparation et les medicaments les contenant | |
| US5334614A (en) | Hydroxylamine derivatives | |
| US5376680A (en) | Oxime derivatives | |
| JP3110049B2 (ja) | 新規イミダゾールリポキシゲナーゼ阻害剤 | |
| EP0233801B1 (fr) | Nouveaux amides substitués, leur préparation et les compositions pharmaceutiques qui les contiennent | |
| WO2004113344A1 (ja) | ピラゾロピリミジン化合物のメタンスルホン酸塩、その結晶およびその製造方法 | |
| JP3165409B2 (ja) | アルキレンジオキシベンゼン誘導体を有効成分とする抗不安薬 |